RN
Rodger Novak
Venture Partner at SR One Capital Management
Switzerland
Overview
Rodger Novak is a seasoned pharmaceutical and biotechnology executive, known for his significant contributions in drug development and clinical research. Currently serving as the Chair of the Board of Directors at AIRNA, Econic Biosciences, and Xap Therapeutics, Novak has also held prominent roles at CRISPR Therapeutics as President & Chair of the Board of Directors, and Sanofi as VP Head TSU Infectious Diseases Global R&D.
Novak's career highlights include founding Nabriva Therapeutics AG as Chief Operating Officer and serving as Deputy Head of Antibiotic Research Institute at Sandoz, showcasing his expertise in leading innovative biotech ventures and driving impactful research in the pharmaceutical industry.
Work Experience
Chair of the Board of Directors
2023 - Current
Chair of the Board of Directors
2022
Chair of the Board of Directors
2020
Venture Partner
2020
SR One is the corporate venture capital arm of GlaxoSmithKline.
Board Member
2014
President & Chair Board of Directors
2017 - 2023
Chief Executive Officer
2013 - 2017
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Raised $407,000,000.00 from SR One and EcoR1 Capital.
VP Head TSU Infectious Diseases Global R&D
2012 - 2013
Founder and Chief Operating Officer
2006 - 2012
Deputy Head Antibiotic Research Institute
2003 - 2005
Position accountable for the management of entire organization in preparation for spin-off from Sandoz/Novartis to foundation of Nabriva.
University Professor
2000 - 2003
Education
MD
1987 - 1992